Physician profile
Pascal Gedeon
NPI 1194872317
$3,025.93
in general payments reported to CMS, 2019-2025
15 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $219 · 2022: $545 · 2023: $773 · 2024: $839 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,262.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $858.55 | 2021-2025 | Biktarvy |
| Viiv Healthcare Company | $721.30 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $385.73 | 2022-2025 | Pifeltro, Delstrigo, Capvaxive |
| Theratechnologies INC. | $248.00 | 2022-2025 | Trogarzo, Egrifta |
| Exact Sciences Corporation | $207.90 | 2023-2025 | Cologuard Collection Kit |
| Janssen Products, LP | $184.00 | 2021-2022 | |
| Janssen Biotech, INC. | $159.39 | 2021-2023 | Symtuza |
| Glaxosmithkline, LLC. | $82.35 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Neurocrine Biosciences, INC. | $43.71 | 2025 | |
| Cranial Technologies, INC | $28.66 | 2022-2024 | Doc Band |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Emd Serono, INC. | $20.86 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.88 | 2023 | |
| Pfizer INC. | $18.97 | 2024 | |
| Abbvie INC. | $18.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascal Gedeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.